We’ve recently updated our valuation analysis.

Prothena Valuation

Is PRTA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PRTA?

Other financial metrics that can be useful for relative valuation.

PRTA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue479.9x
Enterprise Value/EBITDA-15.1x
PEG Ration/a

Price to Book Ratio vs Peers

How does PRTA's PB Ratio compare to its peers?

The above table shows the PB ratio for PRTA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average435.8x
ZLAB Zai Lab
2.8x42.7%US$3.0b
VSBC VitaSpring Biomedical
1734.6xn/aUS$3.1b
RCUS Arcus Biosciences
2.8x-7.3%US$1.9b
DVAX Dynavax Technologies
3.1x-45.3%US$1.6b
PRTA Prothena
7.3x16.5%US$3.0b

Price-To-Book vs Peers: PRTA is good value based on its Price-To-Book Ratio (7.3x) compared to the peer average (435.8x).


Price to Earnings Ratio vs Industry

How does PRTA's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a9.4%
n/an/an/a

Price-To-Book vs Industry: PRTA is expensive based on its Price-To-Book Ratio (7.3x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is PRTA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PRTA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio7.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate PRTA's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of PRTA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PRTA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PRTA's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PRTA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$61.21
US$80.89
+32.1%
23.5%US$120.00US$55.00n/a9
Nov ’23US$63.45
US$77.22
+21.7%
22.0%US$110.00US$52.00n/a9
Oct ’23US$60.63
US$73.78
+21.7%
20.6%US$110.00US$52.00n/a9
Sep ’23US$27.53
US$66.38
+141.1%
26.9%US$100.00US$45.00n/a8
Aug ’23US$29.70
US$66.88
+125.2%
26.3%US$100.00US$45.00n/a8
Jul ’23US$27.89
US$66.88
+139.8%
26.3%US$100.00US$45.00n/a8
Jun ’23US$26.52
US$66.88
+152.2%
26.3%US$100.00US$45.00n/a8
May ’23US$29.16
US$75.43
+158.7%
19.2%US$100.00US$47.00n/a7
Apr ’23US$39.06
US$75.63
+93.6%
17.9%US$100.00US$47.00n/a8
Mar ’23US$33.41
US$76.25
+128.2%
16.1%US$100.00US$52.00n/a8
Feb ’23US$34.66
US$81.63
+135.5%
17.8%US$103.00US$54.00n/a8
Jan ’23US$49.40
US$84.38
+70.8%
12.6%US$103.00US$75.00n/a8
Dec ’22US$46.65
US$84.38
+80.9%
12.6%US$103.00US$75.00n/a8
Nov ’22US$57.46
US$86.00
+49.7%
12.9%US$103.00US$75.00US$63.457
Oct ’22US$70.74
US$80.57
+13.9%
18.6%US$103.00US$57.00US$60.637
Sep ’22US$69.88
US$70.00
+0.2%
11.9%US$82.00US$57.00US$27.537
Aug ’22US$50.10
US$69.14
+38.0%
10.6%US$76.00US$57.00US$29.707
Jul ’22US$52.78
US$60.00
+13.7%
13.2%US$75.00US$49.00US$27.898
Jun ’22US$27.44
US$33.38
+21.6%
29.7%US$45.00US$12.00US$26.528
May ’22US$26.54
US$31.14
+17.3%
29.4%US$43.00US$12.00US$29.167
Apr ’22US$24.74
US$31.14
+25.9%
29.4%US$43.00US$12.00US$39.067
Mar ’22US$21.49
US$28.43
+32.3%
24.9%US$35.00US$12.00US$33.417
Feb ’22US$11.00
US$19.17
+74.2%
32.4%US$28.00US$11.00US$34.666
Jan ’22US$12.01
US$19.17
+59.6%
32.4%US$28.00US$11.00US$49.406
Dec ’21US$11.00
US$16.40
+49.1%
30.0%US$24.00US$11.00US$46.655
Nov ’21US$10.91
US$15.60
+43.0%
31.0%US$24.00US$11.00US$57.465

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies